drugset
drugset / Trial / NCT02208856

Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects

NCT02208856 ↗

Phase 1 Completed 64 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess safety, pharmacokinetics and pharmacodynamics of BIRB 796 BS in escalating single doses, with and without a 64 g fat breakfast at one selected dose.

Timeline

Start
1999-09
Primary completion
1999-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBR 796 BS Unknown 1 mg Oral
Subject BIBR 796 BS Unknown 4 mg Oral
Subject BIBR 796 BS Unknown 15 mg Oral
Subject BIBR 796 BS Unknown 50 mg Oral
Subject BIBR 796 BS Unknown 100 mg Oral
Subject BIBR 796 BS Unknown 200 mg Oral
Subject BIBR 796 BS Unknown 400 mg Oral
Subject BIBR 796 BS Unknown 600 mg Oral

Indications

No indication recorded.